Skip to main content

Health condition · Clinically reviewed

MGUS, a silent precursor that needs watching, not treating.

A common, symptomless finding in older adults - not myeloma, but worth understanding and monitoring for life.

Jump to management
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against British Society for Haematology (BSH) guidelines and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance on risk stratification, surveillance intervals and when specialist referral is warranted.

Key facts

MGUS at a glance.

The essentials, in plain English - what it is, how it’s found, and how it’s followed up in the UK today.

  • What it is

    A monoclonal (M) protein in the blood without meeting the criteria for multiple myeloma or another plasma cell malignancy.

  • How common

    Found incidentally in a notable proportion of people over 70 - prevalence rises steadily with age.

  • Symptoms

    None, by definition. MGUS is asymptomatic and almost always found while investigating something else.

  • Progression risk

    A small but persistent annual risk of progressing to myeloma or a related disorder - roughly 1% per year, lifelong.

  • Treatment

    None required for MGUS itself. The cornerstone of care is active surveillance, not chemotherapy.

  • Who monitors it

    Specialist commissioned haematology, typically 6-monthly to annual review depending on risk category.

Why this guide matters

A finding to understand, not to fear.

MGUS is common, usually benign for life, and - with the right surveillance plan - very manageable. The three points below shape everything else on this page.

  • Surveillance, not treatment

    There is no chemotherapy for MGUS itself - regular blood monitoring is the entire plan, and it works.

  • Risk stratification guides you

    The Mayo Clinic model turns your M protein level and light chain ratio into a clear monitoring schedule, tailored to you.

  • Progression is caught early

    Because MGUS is silent, attending every surveillance appointment is what actually protects you.

How the diagnosis is made

From an incidental finding to a clear surveillance plan.

The steps a UK haematology team will normally follow per BSH guidelines, in order - so you know what to expect and why.

  1. 01

    Finding it

    Incidental finding

    Raised total protein on routine bloods, or investigation of unrelated symptoms such as peripheral neuropathy, first raises the possibility.

  2. 02

    Finding it

    Serum protein electrophoresis

    Identifies and quantifies the M protein - the defining laboratory feature of MGUS.

  3. 03

    Finding it

    Serum free light chain assay

    Assesses the kappa to lambda ratio - an important prognostic marker used in risk stratification.

  4. 04

    Excluding myeloma

    Bloods to exclude myeloma

    Full blood count, calcium and renal function rule out the CRAB features (hypercalcaemia, renal impairment, anaemia, bone lesions) that would suggest myeloma instead.

  5. 05

    Excluding myeloma

    Selective imaging

    A skeletal survey or whole-body MRI/low-dose CT is used selectively if there is clinical suspicion of bone lesions - not routine for classic low-risk MGUS.

  6. 06

    Excluding myeloma

    Bone marrow biopsy if needed

    Not required for typical low-risk MGUS, but performed under specialist haematology if higher-risk features are present or the diagnosis is uncertain.

  7. 07

    Planning

    Mayo Clinic risk stratification

    A validated model using M protein level, type and free light chain ratio sets the surveillance intensity and long-term follow-up plan.

Typical timeline: a first blood test to a confirmed surveillance plan within a few weeks.

Symptoms

What MGUS actually looks like.

Almost nothing, by definition - which is exactly why it is usually found by accident. And the features that mean it’s time to look closer.

  • No symptoms

    By definition MGUS causes no symptoms itself - it is asymptomatic and found incidentally.

  • Raised total protein

    Often the first clue on a routine blood panel done for an unrelated reason.

  • Peripheral neuropathy (IgM MGUS)

    Tingling, numbness or weakness in the feet or hands can prompt the blood tests that uncover IgM MGUS.

  • M protein on electrophoresis

    A discrete monoclonal band on serum protein electrophoresis, at a level below the myeloma threshold.

  • Abnormal light chain ratio

    An abnormal kappa to lambda ratio on the free light chain assay - a key prognostic marker, not a symptom you would notice.

  • No CRAB features

    No hypercalcaemia, renal impairment, anaemia or bone lesions - their presence would instead point to myeloma.

  • Increasing with age

    Detected more often the older the patient, reflecting how common it becomes in later life.

  • Red flag - new symptoms

    Bone pain, fatigue, infections or renal impairment developing over time deserve prompt reassessment for progression.

Management

How MGUS is managed in the UK.

Active surveillance first, last and always - with risk-adapted monitoring and prompt review if anything changes.

  • Active surveillance

    The cornerstone of management - regular monitoring with repeat protein electrophoresis and bloods, typically 6-monthly to annual depending on risk category.

  • No chemotherapy

    Unlike multiple myeloma, active treatment is not indicated for MGUS itself - it does not reduce progression risk and only adds unnecessary toxicity.

  • Risk-adapted monitoring

    Low-risk patients may be reviewed less often; higher-risk patients (larger M protein, abnormal light chain ratio, IgA/IgM subtype) are monitored more closely.

  • Patient education and reassurance

    Explaining the generally benign nature and low annual progression risk, while stressing the importance of attending every surveillance appointment.

  • Prompt symptom review

    New bone pain, fatigue, recurrent infections or renal impairment triggers early reassessment for progression to myeloma or a related disorder.

  • Neuropathy awareness (IgM MGUS)

    Screening and awareness of associated peripheral neuropathy, with specialist neurology input and nerve conduction studies where relevant.

  • MDT specialist haematology

    Ongoing care sits with specialist commissioned haematology, often working alongside Myeloma UK and, where needed, specialist neurology.

  • Lifelong follow-up

    Because the risk of progression never fully disappears, surveillance is typically long-term or lifelong rather than time-limited.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your results and history and can tell you which parts apply to you. If in doubt, get seen.

  • British Society for Haematology (BSH). Guideline on the diagnosis and management of monoclonal gammopathy of undetermined significance.

  • Mayo Clinic. Risk stratification model for MGUS.

  • Myeloma UK. Patient information on MGUS and surveillance.

  • International Myeloma Working Group (IMWG). Diagnostic criteria for plasma cell disorders.

Red flags

When MGUS needs urgent reassessment.

Most MGUS stays stable for life. These are the situations that suggest possible progression - and where earlier haematology input is needed.

  • New bone pain

    Persistent, unexplained bone pain can signal progression to myeloma and warrants prompt bloods and specialist review.

  • Unexplained anaemia

    A falling haemoglobin without another clear cause is one of the CRAB features that distinguishes myeloma from MGUS.

  • Rising calcium

    Hypercalcaemia - thirst, confusion, constipation - needs urgent assessment as a possible myeloma-defining event.

  • Deteriorating renal function

    New or worsening renal impairment in someone with known MGUS should prompt urgent haematology reassessment.

  • Recurrent or severe infections

    Frequent infections can reflect immune paresis associated with progression and should not be dismissed as coincidence.

  • Rapidly rising M protein

    A significant increase in M protein level between surveillance visits raises the likelihood of transformation and needs earlier review.

  • Progressive peripheral neuropathy

    Worsening neuropathy, particularly with IgM MGUS, may indicate an evolving lymphoproliferative disorder such as Waldenstrom macroglobulinaemia.

  • Suspected amyloidosis

    Unexplained heart failure, nephrotic-range proteinuria or macroglossia alongside an M protein should prompt urgent assessment for AL amyloidosis.

  • Missed surveillance appointments

    Because MGUS is silent, missed follow-up is itself a risk - progression can only be caught early if monitoring continues.

Living with it

A benign finding, with a clear watch-and-wait plan.

Four things that make the biggest difference over the years - understanding your low risk, keeping appointments, reporting new symptoms and knowing your risk category.

A quiet reminder

A diagnosis of MGUS is not a diagnosis of cancer.

It is a label for something to keep an eye on - most people carry it for decades without incident.

  1. 01 Reassure

    Most MGUS never progresses

    The large majority of people with MGUS live their whole lives without it becoming myeloma - the annual risk is small and cumulative, not a certainty.

  2. 02 Attend

    Keep every surveillance appointment

    Because there are no symptoms to watch for, blood tests are the only way progression is caught early - don’t let appointments lapse.

  3. 03 Report

    Flag new symptoms promptly

    Bone pain, unusual fatigue, infections or numbness are worth mentioning to your haematology team between scheduled visits.

  4. 04 Understand

    Know your risk category

    Ask your team where you sit on the Mayo Clinic risk model - it explains why your monitoring interval is what it is.

Frequently asked

Everything we get asked about MGUS.

Quick answers on diagnosis, progression risk and how surveillance works.

  • What is MGUS?

    Monoclonal gammopathy of undetermined significance is the presence of a monoclonal (M) protein in the blood without meeting the diagnostic criteria for multiple myeloma or another related plasma cell or lymphoid malignancy. It is considered a precursor condition rather than a cancer.

  • Does MGUS cause any symptoms?

    No - by definition MGUS is asymptomatic. It is almost always discovered incidentally, for example during investigation of unrelated symptoms, a raised total protein on routine bloods, or workup for peripheral neuropathy.

  • Will MGUS turn into cancer?

    Most people with MGUS never progress. There is a small but persistent annual risk, in the region of about 1%, of developing multiple myeloma or a related condition such as Waldenstrom macroglobulinaemia, AL amyloidosis or lymphoma - which is why lifelong surveillance matters.

  • How is MGUS diagnosed?

    Serum protein electrophoresis identifies and quantifies the M protein, and a serum free light chain assay checks the kappa to lambda ratio. Full blood count, calcium and renal function are checked to exclude myeloma-defining events, with bone marrow biopsy or imaging reserved for higher-risk or uncertain cases.

  • What treatment do I need for MGUS?

    None, for MGUS itself. Active treatment such as chemotherapy is not used because it does not reduce the risk of progression and only adds treatment burden. The mainstay of care is active surveillance, typically 6-monthly to annual review depending on your risk category.

  • Why does the monitoring frequency differ between people?

    Risk stratification models, such as the Mayo Clinic model, use the M protein level, its type and the free light chain ratio to estimate progression risk. Higher-risk patients - larger M protein, abnormal light chain ratio, IgA or IgM subtype - are monitored more closely than lower-risk patients.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.